So, combination of both nanomaterial and the PRAP-1 inhibitor and labeling them by 99mTc and also the exploitation of the advantage of the active targeting of the nano-system to tumor cells give a high potential opportunity to have a novel potent drug that may start a new era in tumor theragnosis. The gene discussed is PRAP1; the disease is neoplasm.